NCT06956053View on ClinicalTrials.gov

Personalized Optimization of Antibiotic Therapy in Pulmonary Sepsis Critically Ill Patients Through Application of Rapid Microbiological Diagnostic Technologies and Pharmacokinetic/Pharmacodynamic Modelling

NANot yet recruitingINTERVENTIONAL

Enrollment

658

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

May 30, 2028

Study Completion Date

November 30, 2028

Conditions

Pulmonary Sepsis

Interventions

DIAGNOSTIC_TEST

Rapid ID/AST method

"1. BioFire® Film Array® Blood Culture Identification 2 BCID2 panel, bioMérieux/BioFire Diagnostics, CE marked (FDA cleared)~2. BioFire® FilmArray® Pneumonia Panels, CE marked (FDA cleared)~3. SPECIFIC REVEAL® Rapid Antimicrobial Susceptibility test (AST) System, bioMérieux/Specific Diagnostics, CE-IVD and -IVDR marked"

DIAGNOSTIC_TEST

Conventional biological methods

Usual care

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER